Skip to main content
. 2024 Feb 14;24:73. doi: 10.1186/s12876-024-03147-5

Table 3.

The HCV RNA undetectable rates and adverse effects among time-points

Parameters ECS(n = 94) DNV (n = 84) All (n = 178) P
HCV RNA undetectable
 4-week treatment 84 (88.42%) 61 (72.62%) 145 (81.46%) 0.004
 At the end of treatment 94(100.00%) 82 (97.62%) 176 (94.25%) 0.132
 SVR12 94(100.00%) 84(100.00%) 178 (100.00%) 1.000
Adverse effects 0.331
 No 92 (97.87%) 80 (95.24%) 172 (96.63%)
 Yes 2 (2.13%) 4 (4.76%) 6 (3.37%)

SVR12, Undetectable HCV RNA 12 weeks after the end of treatment